Short Interest in GH Research PLC (NASDAQ:GHRS) Increases By 7.3%

GH Research PLC (NASDAQ:GHRS - Get Free Report) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 1,910,000 shares, a growth of 7.3% from the October 15th total of 1,780,000 shares. Based on an average daily trading volume, of 48,700 shares, the short-interest ratio is currently 39.2 days. Currently, 6.3% of the shares of the stock are short sold.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP lifted its holdings in GH Research PLC (NASDAQ:GHRS - Free Report) by 80.1% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 3,310,563 shares of the company's stock after purchasing an additional 1,471,946 shares during the period. GH Research comprises 9.1% of Lynx1 Capital Management LP's holdings, making the stock its 6th biggest position. Lynx1 Capital Management LP owned 6.36% of GH Research worth $35,291,000 as of its most recent SEC filing. 56.90% of the stock is currently owned by institutional investors.

GH Research Stock Up 4.2 %

NASDAQ:GHRS traded up $0.38 during mid-day trading on Monday, hitting $9.47. 159,750 shares of the stock traded hands, compared to its average volume of 79,965. The stock has a market capitalization of $492.72 million, a price-to-earnings ratio of -11.99 and a beta of 0.74. GH Research has a 52 week low of $5.05 and a 52 week high of $14.99. The firm's 50 day moving average is $7.78 and its two-hundred day moving average is $10.34.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.03. As a group, research analysts predict that GH Research will post -0.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on GHRS. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of GH Research in a report on Thursday, September 5th. JMP Securities reaffirmed a "market outperform" rating and issued a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th. Finally, Canaccord Genuity Group cut their target price on GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.